TNFRSF17 and plasma cell myeloma: In multiple myeloma, BCMA is the target antigen of choice commonly used in clinical trials of CAR-T cells [175, 176]. CAR T cells are also effective in treating acute and chronic leukemia and B lymphoma cells, where CD19 antigen is widely expressed.